Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu +5 more
wiley +1 more source
M5 positive allosteric modulation alleviates parkinsonian motor deficits. [PDF]
Chambers NE +5 more
europepmc +1 more source
From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui +5 more
wiley +1 more source
Agonist-specific conformational dynamics at the β<sub>2</sub>-adrenoceptor dictate allosteric modulation of Gαs signalling and bronchodilation. [PDF]
Shah SD +7 more
europepmc +1 more source
Protein-Driven Copper Redox Regulation: Uncovering the Role of Disulphide Bonds and Allosteric Modulation. [PDF]
Sternke-Hoffmann R +9 more
europepmc +1 more source
Microtubule Destabilizing Kinesins: A Historical Perspective and Thoughts for the Future
ABSTRACT The microtubule cytoskeleton plays critical roles in multiple cellular processes such as mitotic spindle assembly and chromosome segregation. Cells contain a number of microtubule‐associated proteins that regulate microtubule dynamics both temporally and spatially in cells. The microtubule depolymerizing kinesins include members of the Kinesin‐
Claire E. Walczak
wiley +1 more source
Molecular determinants of allosteric modulation of protein disulfide isomerase by small-molecule b'-ligands. [PDF]
Ponzar N +6 more
europepmc +1 more source
Allosteric Modulators of Drug Targets [PDF]
openaire +2 more sources
Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Selective positive allosteric modulation of β<sub>2</sub>AR using antibody fragments targeting the third intracellular loop. [PDF]
Sánchez Rivas EJ +8 more
europepmc +1 more source

